Skip to main content
PMC home page
Springer logoLink to Springer
. 2017 May 15;68(1):1–6. doi: 10.1007/s10858-017-0107-8

Solvent-accessibility of discrete residue positions in the polypeptide hormone glucagon by 19F-NMR observation of 4-fluorophenylalanine

Yaguang Hou 1,2,3,6,#, Wanhui Hu 1,#, Xiaona Li 4, John J Skinner 1, Dongsheng Liu 1, Kurt Wüthrich 1,5,✉
PMCID: PMC5487752  PMID: 28508109

Abstract

The amino acid 4-fluoro-l-phenylalanine (4F-Phe) was introduced at the positions of Phe6 and Phe22 in the 29-residue polypeptide hormone glucagon by expressing glucagon in E. coli in the presence of an excess of 4F-Phe. Glucagon regulates blood glucose homeostasis by interaction with the glucagon receptor (GCGR), a class B GPCR. By referencing to the 4F-Phe chemical shifts at varying D2O concentrations, the solvent exposure of the two Phe sites along the glucagon sequence was determined, showing that 4F-Phe6 was fully solvent exposed and 4F-Phe22 was only partially exposed. The incorporation of fluorine atoms in polypeptide hormones paves the way for novel studies of their interactions with membrane-spanning receptors, specifically by differentiating between effects on the solvent accessibility, the line shapes, and the chemical shifts from interactions with lipids, detergents and proteins. Studies of interactions of GCGR with ligands in solution is at this point of keen interest, given that recent crystallographic studies revealed that an apparent small molecule antagonist actually binds as an allosteric effector at a distance of ~20 Å from the orthosteric ligand binding site (Jazayeri et al., in Nature 533:274–277, 2016).

Keywords: 19F-NMR, Glucagon, 19F chemical shift, Solvent exposure from D2O effects

Introduction

This paper describes work toward the mapping of interactions between the polypeptide hormone glucagon and the glucagon receptor (GCGR), which is a Class B G protein-coupled receptor (GPCR) (Hollenstein et al. 2014). Polypeptides can adopt a much wider range of conformations than the small-molecule drugs bound in most GPCR crystal structures (e.g., Chrencik et al. 2015; Hua et al. 2016; Jazayeri et al. 2016). Nuclear magnetic resonance (NMR) spectroscopy is a powerful tool for determining polypeptide conformations (e.g., Wüthrich 2003), but, due to line broadening and signal overlap, much of the NMR information is typically lost upon binding of the polypeptides to larger molecules. We plan to overcome these limitations by using 19F-NMR probes, which have chemical shifts that are well separated from those of the macromolecular background (Didenko et al. 2013). The 19F van der Waals radius of 1.35 Å is close to that of hydrogen (1.20 Å), and 19F is widely considered as being isosteric with 1H (Marsh and Suzuki 2014). High sensitivity to detection and large chemical shift dispersion have enabled 19F-NMR studies of protein folding/unfolding, intermolecular interactions and conformational dynamics (Chen et al. 2013; Didenko et al. 2013; Kitevski-LeBlanc and Prosser 2012). 19F-NMR studies of GPCRs have so far mainly been based on post-translational chemical conjugation with cysteine sulfhydryl groups, for example, with TET (2,2,2-trifluoroethanethiol) (Klein-Seetharaman et al. 1999; Liu et al. 2012) or BTFA (3-bromo-1,1,1-trifluoroacetone) (Kim et al. 2013). Application of this approach for the labeling of polypeptide ligands changes the chemical structure much more extensively than the incorporation of 19F-containing amino acids. We therefore use the latter strategy in this work based on supplying E. coli cells with an excess of 4F-Phe, which was then incorporated via the naturally occurring tRNAPhe.

Glucagon is a 29-amino acid polypeptide hormone processed from the precursor proglucagon in pancreatic α-cells (Jiang and Zhang 2003). Glucagon plays a crucial role in the regulation of blood glucose homeostasis by stimulating glycogenolysis and gluconeogenesis in hepatocytes (Mayo et al. 2003) and lipolysis in adipocytes (Perea et al. 1995). Glucagon functions by binding to and thus activating GCGR, which is one of the 15 members of the secretin-like (class B) family of human GPCRs (Hollenstein et al. 2014; Siu et al. 2013). Binding of glucagon to GCGR results in activation of intracellular G proteins and adenylate cyclase, and the resulting increase in intracellular cyclic adenosine monophosphate (cAMP) levels initiates the next steps in the signaling pathway (Jiang and Zhang 2003; Rodgers 2012).

Here, glucagon was labeled by substituting Phe in positions 6 and 22 with the non-proteinogenic amino acid 4-fluoro-l-phenylalanine (4F-Phe) (Bann and Frieden 2004; Li and Frieden 2005). The solvent isotope effect on the 19F chemical shift at variable D2O concentrations (Hansen et al. 1985; Kitevski-LeBlanc et al. 2009; Shi et al. 2011) was used to investigate site-specific solvent accessibility of glucagon (Fig. 1). As a control, 1D 1H-NMR and cAMP assays were used to show that 4F-Phe incorporation caused at most minimal perturbations of glucagon conformation and activity (Fig. 2). Our work lays a foundation for studying glucagon conformation and dynamics when interacting with GCGR with and without the presence of intramolecular partner proteins. Further investigation of glucagon–GCGR interactions in solution is particularly important given recent crystallographic evidence that an apparent small-molecule antagonist actually binds as an allosteric effector to the intracellular side of GCGR at the distance of ~20 Å from the orthosteric ligand binding site (Jazayeri et al. 2016).

Fig. 1.

Fig. 1

Open in a new tab

1D 19F-NMR spectra at 470 and 565 MHz of three glucagon variants and of 4F-Phe. a Four 470 MHz spectra of 4 mM 4F-Phe in water containing, respectively, 10, 40, 70 and 100% D2O. The percentage of D2O and the measured chemical shift are shown above each spectrum. b 565 MHz spectra of 0.3 mM solutions of 4F-Phe-labeled glucagon variants in H2O solution containing 10% D2O; the doubly-labeled glucagon was also measured in DMSO solution. For the two [4F-Phe6,22]-glucagon spectra, the integration traces and relative peak intensities are shown in red. These spectra were recorded with a Bruker Avance-600 spectrometer equipped with a cryogenic TCI probehead; no 1H-decoupling was applied during 19F-detection. c Four spectra of 0.1 mM [4F-Phe6,22]-glucagon in water containing, respectively, 10, 40, 70 and 100% D2O, as shown at the top of the peaks, where the measured chemical shifts are also indicated. d Plots versus the D2O concentration of the 19F chemical shifts measured in (a) and (c) for 4F-Phe (filled circle), and for 4F-Phe6 (filled square) and 4F-Phe22 (filled triangle) in [4F-Phe6,22]-glucagon

Fig. 2.

Fig. 2

Open in a new tab

Chemical structure and biophysical/biochemical characterization of [4F-Phe6,22]-glucagon. a Chemical structure of 4-fluoro-l-phenylalanine (4F-Phe). b Scheme of the Trx-His-S-glucagon fusion protein used for glucagon expression, where a Trx tag, a 6 × His tag, an S tag, and an enterokinase cleavage site (DDDDK↓) precede glucagon. In the amino acid sequence of glucagon, Phe6 and Phe22 are highlighted in red. c SDS–PAGE gel documenting the expression and purification of glucagon. Lane 1 crude extract of uninduced E. coli BL21 cells (DE3); lane 2 cell extract at 5 h after induction; lanes 3 and 4 supernatant and pellet, respectively, after sonication; lane 5 flow-through from the Co2+-TALON column; lane 6 Co2+-TALON elution with 250 mM imidazole; lane 7 same as 6 after enterokinase treatment; lane 8 same as 7 after HPLC and lyophilization; lane 9 molecular weight markers. d 1D 1H-NMR spectra of [4F-Phe6,22]-glucagon and wild type glucagon. The spectral region from 10 to 5 ppm is shown, with 7.2 to 7.0 ppm enlarged on the right. e Mass spectrometry of glucagon. f Mass spectrometry of the [4F-Phe6.22]-glucagon preparation used for the 19F-NMR measurements. In e and f, the peaks represent the molecules with four positive charges by additional protons, and the m/z ratios of the highest peaks of these peak clusters are indicated. In f, an estimate of the relative abundance of unlabeled, singly-labeled and doubly-labeled glucagon is indicated below the m/z ratio of each peak, respectively. g cAMP assays. cAMP formation was monitored by the fluorescence ratio 665/615 nm. The error bars represent the standard error of the mean. A sigmoidal fit of the data is shown. The EC50 values for glucagon and [4F-Phe6,22]-glucagon were 0.249 and 0.304 μM, respectively

19F-NMR study of glucagon solvent accessibility at discrete sequence locations

The two phenylalanine residues in positions 6 and 22 of the glucagon amino acid sequence were substituted by 4F-Phe (Fig. 2a) in the recombinant variant polypeptide (Fig. 2b) by incubating E. coli cells with an excess of 4F-Phe, which was then incorporated via the naturally occurring tRNAPhe. 19F-NMR spectra were obtained for 4F-Phe and for 4F-Phe-labeled glucagon in H2O/D2O solutions with variable D2O concentrations (Fig. 1a, c). Samples of 4 mM 4F-Phe and 0.1 mM 4F-Phe-labeled glucagon in acidic water (pH* 2.5) were prepared with addition of D2O at 10% increments for 19F-NMR spectra collection. Within the NMR tube, a capillary containing 5 mM trifluoroacetic acid (TFA) was used as an external standard, and 19F chemical shift values were referenced to TFA at −76.55 ppm. Except for the spectra shown in Fig. 1b (see the figure caption for details), the 19F-NMR experiments were performed at 298 K on a Bruker AVANCE-500 spectrometer equipped with a room temperature BBO probehead (Bruker Biospin), using the pulse program zgfhigqn30.2 with 1H-decoupling during 19F-detection. The 19F frequency was about 470 MHz, and the number of scans was 128 for 4F-Phe, and 2048 for 4F-Phe-labeled glucagon. Prior to Fourier transformation, the time-domain NMR data were multiplied with an exponential function with line broadening factors of 1 and 5 Hz for 4F-Phe and 4F-Phe-labeled glucagon, respectively.

The 19F-NMR signals for all the samples shifted upfield with increasing D2O/H2O ratio. For 4F-Phe, the 19F chemical shift difference between 10 and 100% D2O was about 0.14 ppm (Fig. 1a). This is consistent with previous reports on other systems (Hansen et al. 1985; Kitevski-LeBlanc et al. 2009; Shi et al. 2011).

For [4F-Phe6,22]-glucagon, the 19F-NMR spectrum showed two peaks, representing the two fluorine-labeled sites (Fig. 1b), which had been introduced by incubating E. coli cells with an excess of 4F-Phe. In order to assign the two peaks, two glucagon mutants were designed, as detailed in Fig. 1b. The 19F-NMR spectra of each of these two mutants showed only one resonance, with the 4F-Phe6 signal upfield from the 4F-Phe22 signal (Fig. 1b).

In the 19F-NMR spectrum, 4F-Phe6 had a significantly narrower resonance peak than 4F-Phe22. For 4F-Phe6, the full widths at half peak height were about 13, 13, 14 and 15 Hz at the D2O concentrations of 10, 40, 70 and 100%, respectively, and for 4F-Phe22 the corresponding values were about 20, 23, 24 and 23 Hz, respectively (Fig. 1c).

Just as with 4F-Phe, the 19F chemical shift values of both labels in glucagon decreased linearly with increasing D2O concentration (Fig. 1d). The maximum 19F chemical shift differences were 0.14 ppm for 4F-Phe6 and 0.08 ppm for 4F-Phe22. These differences suggest that position 6 has full solvent exposure, whereas position 22 is only partially exposed to solvent. This result is readily rationalized by structural data from previous 1H-NMR studies of glucagon in acidic aqueous solutions, which showed that the region around residue six is flexibly disordered and Phe22 is part of a hydrophobic cluster formed by the residues –Phe22–Val23–Gln24–Trp25– (Boesch et al. 1978).

Glucagon conformation and biological activity are preserved after 4F-Phe incorporation

The glucagon fusion construct used for expression in E. coli contained an N-terminal Trx (thioredoxin) tag, a His tag, an S tag, and an enterokinase cleavage site (LaVallie et al. 1993) (Fig. 2a, b). For expression we used an M9 culture medium. 0.5 g/L of 4F-Phe was added when the OD600 reached 0.6. After 30 min, protein expression was induced with 0.5 mM IPTG, and cells were subsequently grown overnight at 25 °C. We did not notice a possible toxic effect of 4F-Phe at the aforementioned concentration. After purification with a Co2+-TALON superflow affinity column (Clontech), the proteins were incubated with enterokinase (BBI Life Science) to cleave the N-terminal Trx tag, His tag, and S tag. Expression and purification of glucagon were analyzed by SDS/PAGE (Fig. 2c). The yield of purified glucagon was 3 mg from 1 L of E. coli culture.

Glucagon has poor solubility in aqueous buffers at physiological pH. Therefore, Trx fusion was used as a solubility enhancement tag to express glucagon (Chabenne et al. 2010). The N-terminal histidine residue of glucagon has an important role in modulating the GCGR signaling pathway (Sueiras-Diaz et al. 1984). Here, we therefore used enterokinase to cleave the Trx-His-S-glucagon fusion protein; this protease cleaves after lysine, resulting in no additional residues at the glucagon N-terminus, as shown by mass spectroscopy (Fig. 2e, f).

The incorporation of 4F-Phe into glucagon was analyzed using liquid chromatography electro-spray ionization mass spectrometry (LCESI-MS) (Fig. 2e, f). For unlabeled glucagon, the peaks were consistent with the theoretical molecular weight (3482.5 Da). For [4F-Phe6,22]-glucagon, because of variable extents of 4F-Phe incorporation, there were three peak clusters with molecular weights of 3482.50, 3500.61 and 3518.59 Da, which were assigned to unlabeled, singly and doubly 4F-Phe-labeled glucagon, respectively, each carrying 4 H+. According to the relative peak intensities, we estimated that the relative abundance of unlabeled, singly-labeled and doubly-labeled glucagon were about 3, 36, and 61%, respectively.

1D 1H-NMR was applied to detect the influence of 19F-labeling on the conformation of glucagon. Samples of [4F-Phe6,22]-glucagon and wild type glucagon in 400 µL of acidic water containing 10% D2O (pH* 2.5) were prepared, and the 1H-NMR experiments were performed at 298 K on the aforementioned Bruker AVANCE-500 spectrometer. The 1H-NMR spectra of [4F-Phe6,22]-glucagon and wild type glucagon were almost identical; some differences in the spectral region from 7.0 to 7.2 ppm are likely due to effects from the substitution of Hζ by 19F on the other Phe ring hydrogens (Fig. 2d).

Glucagon activates adenylate cyclase by binding to GCGR and activating G proteins (Bataille and Dalle 2014). We applied cAMP assays (Norskov-Lauritsen et al. 2014) to test [4F-Phe6,22]-glucagon for activity. The binding curves demonstrated that [4F-Phe6,22]-glucagon had similar activity as glucagon (Fig. 2g), indicating that this 19F-labeling does not affect glucagon signaling activity.

Discussion

In the present paper we used recombinant technology to replace Phe in glucagon with the nonproteinogenic amino acid 4F-Phe by incubating E. coli cells with an excess of 4F-Phe, since replacement by 4F-Phe causes minimal perturbation of the covalent structure. As hoped for, this substitution had at most minimal effects on the structure and the biological activity of glucagon. The same approach could of course be used for the introduction of more attractive 19F-labels such as, for example, CF3-Phe (Chen et al. 2013).

Mass-spectrometric (MS) analysis indicated that about 80% of Phe was replaced by 4F-Phe with the experimental conditions used. Combined with the 19F-NMR spectra in Fig. 1b, we can further conclude that the two Phe-positions in glucagon are nearly equally occupied by 4F-Phe in [4F-Phe6,22]-glucagon. The MS data (Fig. 2f) also showed that the procedure used yielded a mixture of singly and doubly 4F-Phe-labeled glucagon. However, since the chemical shifts and line shapes of the two labeling sites are identical in singly and doubly labeled glucagon (Fig. 1b), interaction studies with GCGR could be performed with either one of the three constructs in Fig. 1b, or with a mixture of singly and doubly labeled glucagon as obtained here.

It is reassuring to note that the observations on solvent accessibility and line shapes for 4F-Phe6 and 4F-Phe22 can be rationalized with a previous NMR structure determination of glucagon in acidic aqueous solution, which showed that Phe6 is in a flexibly disordered region of the polypeptide, while Phe22 is part of a hydrophobic cluster (Boesch et al. 1978). The chemical shift difference between 4F-Phe6 and 4F-Phe22 of 0.28 ppm, which enables to use both labeling sites for independent observations in a single experiment, reflects the locally different conformations along the glucagon chain. This is clearly documented by comparison of the 19F-NMR spectra of [4F-Phe6,22]-glucagon in H2O and DMSO (Fig. 1b); it has been shown previously that DMSO reversibly unfolds the hydrophobic cluster formed by the glucagon residues 22–25 (Boesch et al. 1978; Bundi et al. 1978). It will be interesting to investigate interactions of [4Phe6,22]-glucagon with GCGR not only on the basis of solvent accessibility and line shape variations due to decreased mobility of the bound glucagon and possibly conformational microheterogeneity, but also on the basis of the chemical shifts, which may provide information on conformational changes of the glucagon upon binding. Further investigation of glucagon binding to GCGR in solution will be critical for exploring of the role of the newly discovered allosteric site located at the distance of ~20 Å from the orthosteric ligand binding site of GCGR (Jazayeri et al. 2016).

Acknowledgements

The authors acknowledge financial support by ShanghaiTech University, the Shanghai Municipal Government, the “Users with Excellence” Project (2015HSC-UE012) of the Hefei Science Center, a Grant to Dongsheng Liu from the National Natural Science Foundation of China (No. 31670733), and a Shanghai 1000-talents award to Kurt Wüthrich.

Footnotes

Yaguang Hou and Wanhui Hu contributed equally to this work.

References

  1. Bann JG, Frieden C. Folding and domain-domain interactions of the chaperone PapD measured by 19F NMR. BioChemistry. 2004;43:13775–13786. doi: 10.1021/bi048614u. [DOI] [PubMed] [Google Scholar]
  2. Bataille D, Dalle S. The forgotten members of the glucagon family. Diabetes Res Clin Pract. 2014;106:1–10. doi: 10.1016/j.diabres.2014.06.010. [DOI] [PubMed] [Google Scholar]
  3. Boesch C, Bundi A, Oppliger M, Wüthrich K. 1H nuclear-magnetic-resonance studies of the molecular conformation of monomeric glucagon in aqueous solution. Eur J Biochem. 1978;91:209–214. doi: 10.1111/j.1432-1033.1978.tb20953.x. [DOI] [PubMed] [Google Scholar]
  4. Bundi A, Andreatta RH, Wüthrich K. Characterisation of a local structure in the synthetic parathyroid hormone fragment 1–34 by 1 H nuclear-magnetic-resonance techniques. Eur J Biochem. 1978;91:201–208. doi: 10.1111/j.1432-1033.1978.tb20952.x. [DOI] [PubMed] [Google Scholar]
  5. Chabenne JR, DiMarchi MA, Gelfanov VM, DiMarchi RD. Optimization of the native glucagon sequence for medicinal purposes. J Diabetes Sci Technol. 2010;4:1322–1331. doi: 10.1177/193229681000400605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen H, Viel S, Ziarelli F, Peng L. 19F NMR: a valuable tool for studying biological events. Chem Soc Rev. 2013;42:7971–7982. doi: 10.1039/c3cs60129c. [DOI] [PubMed] [Google Scholar]
  7. Chrencik JE, Roth CB, Terakado M, Kurata H, Omi R, Kihara Y, Warshaviak D, Nakade S, Asmar-Rovira G, Mileni M, Mizuno H, Griffith MT, Rodgers C, Han GW, Velasquez J, Chun J, Stevens RC, Hanson MA. Crystal structure of antagonist bound human lysophosphatidic acid receptor 1. Cell. 2015;161:1633–1643. doi: 10.1016/j.cell.2015.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Didenko T, Liu JJ, Horst R, Stevens RC, Wüthrich K. Fluorine-19 NMR of integral membrane proteins illustrated with studies of GPCRs. Curr Opin Struct Biol. 2013;23:740–747. doi: 10.1016/j.sbi.2013.07.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hansen PE, Dettman HD, Sykes BD. Solvent-induced deuterium isotope effects on 19F chemical shifts of some substituted fluorobenzenes. J Magn Reson. 1985;62:487–496. [Google Scholar]
  10. Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, Stevens RC. Insights into the structure of class B GPCRs. Trends Pharmacol Sci. 2014;35:12–22. doi: 10.1016/j.tips.2013.11.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, Zhao S, Shui W, Li S, Korde A, Laprairie RB, Stahl EL, Ho J-H, Zvonok N, Zhou H, Kufareva I, Wu B, Zhao Q, Hanson MA, Bohn LM, Makriyannis A, Stevens RC, Liu Z-J. Crystal structure of the human cannabinoid receptor CB1. Cell. 2016;167(750–762):e714. doi: 10.1016/j.cell.2016.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jazayeri A, Dore AS, Lamb D, Krishnamurthy H, Southall SM, Baig AH, Bortolato A, Koglin M, Robertson NJ, Errey JC, Andrews SP, Teobald I, Brown AJ, Cooke RM, Weir M, Marshall FH. Extra-helical binding site of a glucagon receptor antagonist. Nature. 2016;533:274–277. doi: 10.1038/nature17414. [DOI] [PubMed] [Google Scholar]
  13. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2003;284:E671–E678. doi: 10.1152/ajpendo.00492.2002. [DOI] [PubMed] [Google Scholar]
  14. Kim TH, Chung KY, Manglik A, Hansen AL, Dror RO, Mildorf TJ, Shaw DE, Kobilka BK, Prosser RS. The role of ligands on the equilibria between functional states of a G protein-coupled receptor. J Am Chem Soc. 2013;135:9465–9474. doi: 10.1021/ja404305k. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kitevski-LeBlanc JL, Prosser RS. Current applications of 19F NMR to studies of protein structure and dynamics. Prog Nucl Magn Reson Spectrosc. 2012;62:1–33. doi: 10.1016/j.pnmrs.2011.06.003. [DOI] [PubMed] [Google Scholar]
  16. Kitevski-LeBlanc JL, Evanics F, Prosser RS. Approaches for the measurement of solvent exposure in proteins by 19F NMR. J Biomol NMR. 2009;45:255–264. doi: 10.1007/s10858-009-9359-2. [DOI] [PubMed] [Google Scholar]
  17. Klein-Seetharaman J, Getmanova EV, Loewen MC, Reeves PJ, Khorana HG. NMR spectroscopy in studies of light-induced structural changes in mammalian rhodopsin: applicability of solution (19)F NMR. Proc Natl Acad Sci USA. 1999;96:13744–13749. doi: 10.1073/pnas.96.24.13744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. LaVallie ER, DiBlasio EA, Kovacic S, Grant KL, Schendel PF, McCoy JM. A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology. 1993;11:187–193. doi: 10.1038/nbt0293-187. [DOI] [PubMed] [Google Scholar]
  19. Li H, Frieden C. NMR studies of 4-19F-phenylalanine-labeled intestinal fatty acid binding protein: evidence for conformational heterogeneity in the native state. Biochemistry. 2005;44:2369–2377. doi: 10.1021/bi047600l. [DOI] [PubMed] [Google Scholar]
  20. Liu JJ, Horst R, Katritch V, Stevens RC, Wüthrich K. Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR. Science. 2012;335:1106–1110. doi: 10.1126/science.1215802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Marsh EN, Suzuki Y. Using (19)F NMR to probe biological interactions of proteins and peptides. ACS Chem Biol. 2014;9:1242–1250. doi: 10.1021/cb500111u. [DOI] [PubMed] [Google Scholar]
  22. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ. International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003;55:167–194. doi: 10.1124/pr.55.1.6. [DOI] [PubMed] [Google Scholar]
  23. Norskov-Lauritsen L, Thomsen AR, Brauner-Osborne H. G protein-coupled receptor signaling analysis using homogenous time-resolved Forster resonance energy transfer (HTRF(R)) technology. Int J Mol Sci. 2014;15:2554–2572. doi: 10.3390/ijms15022554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Perea A, Clemente F, Martinell J, Villanueva-Penacarrillo ML, Valverde I. Physiological effect of glucagon in human isolated adipocytes. Horm Metab Res. 1995;27:372–375. doi: 10.1055/s-2007-979981. [DOI] [PubMed] [Google Scholar]
  25. Rodgers RL. Glucagon and cyclic AMP: time to turn the page? Curr Diabetes Rev. 2012;8:362–381. doi: 10.2174/157339912802083540. [DOI] [PubMed] [Google Scholar]
  26. Shi P, Li D, Chen H, Xiong Y, Tian C. Site-specific solvent exposure analysis of a membrane protein using unnatural amino acids and 19F nuclear magnetic resonance. Biochem Biophys Res Commun. 2011;414:379–383. doi: 10.1016/j.bbrc.2011.09.082. [DOI] [PubMed] [Google Scholar]
  27. Siu FY, He M, de Graaf C, Han GW, Yang D, Zhang Z, Zhou C, Xu Q, Wacker D, Joseph JS, Liu W, Lau J, Cherezov V, Katritch V, Wang MW, Stevens RC. Structure of the human glucagon class B G-protein-coupled receptor. Nature. 2013;499:444–449. doi: 10.1038/nature12393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sueiras-Diaz J, Lance VA, Murphy WA, Coy DH. Structure-activity studies on the N-terminal region of glucagon. J Med Chem. 1984;27:310–315. doi: 10.1021/jm00369a014. [DOI] [PubMed] [Google Scholar]
  29. Wüthrich K. NMR studies of structure and function of biological macromolecules. Angew Chem Int Ed Engl. 2003;42:3340–3363. doi: 10.1002/anie.200300595. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Biomolecular Nmr are provided here courtesy of Springer

RESOURCES